Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.39B P/E - EPS this Y -23.10% Ern Qtrly Grth -
Income -93.72M Forward P/E -13.64 EPS next Y -37.50% 50D Avg Chg -25.00%
Sales - PEG -1.12 EPS past 5Y - 200D Avg Chg 10.00%
Dividend N/A Price/Book 3.60 EPS next 5Y 40.00% 52W High Chg -46.00%
Recommedations 1.40 Quick Ratio 29.38 Shares Outstanding 110.27M 52W Low Chg 449.00%
Insider Own 6.00% ROA -12.78% Shares Float 104.36M Beta 1.02
Inst Own 75.55% ROE -17.55% Shares Shorted/Prior 16.83M/12.31M Price 13.91
Gross Margin - Profit Margin - Avg. Volume 2,851,827 Target Price 113.36
Oper. Margin - Earnings Date Jul 24 Volume 1,253,300 Change -1.77%
About Viking Therapeutics, Inc.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Viking Therapeutics, Inc. News
07/24/24 Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
07/24/24 The Zacks Analyst Blog Highlights Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences
07/23/24 Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
07/22/24 Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.
07/21/24 This market expert warns real estate woes may not be limited to commercial — 3 'idiosyncratic' stocks he likes
07/20/24 3 Monster Stocks in the Making to Buy Right Now
07/19/24 Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know
07/19/24 Should Viking (VKTX) Stock be in Your Portfolio Pre-Q2 Earnings?
07/19/24 Is Viking Therapeutics a Millionaire-Maker?
07/18/24 Why the Market Dipped But Viking Therapeutics, Inc. (VKTX) Gained Today
07/18/24 3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition
07/17/24 Eli Lilly, Novo Nordisk — And Their Rivals — Skid On Roche's Weight-Loss Drug Results
07/17/24 Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024
07/17/24 Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
07/17/24 Is Viking Therapeutics the Best Biotech Stock for You?
07/12/24 We're Not Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn
07/12/24 The 3 Most Undervalued Biotech Stocks to Buy in July 2024
07/11/24 Is Viking Therapeutics Stock Running Out of Steam?
07/10/24 Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics
07/08/24 3 Overlooked Giants-in-the-Making for Patient Investors
VKTX Chatroom

User Image uknic Posted - 1 minute ago

@WESI_CEO $vktx

User Image Erikg19 Posted - 9 minutes ago

$VKTX today's data and info should change the Outlook for Viking even more and permanently. It is set up for going into potential production or massive buyout offer which I'm not even sure they would entertain. We'll see.

User Image AbraKeeperOfThe12Bees Posted - 37 minutes ago

$VKTX Wirecard 2.0?

User Image Magnificient Posted - 1 hour ago

$VKTX which Phase is Retaturid?

User Image Galactic_Stock_Savant Posted - 1 hour ago

$VKTX big pharma is gonna be scrambling tomorrow no other weight drug is even out of phase 2 … lly and novo gonna take a huge hit from this competition and we are gonna steal a large part of their market once we are approved fully in 8-9 months

User Image Magnificient Posted - 1 hour ago

$VKTX ring the bells. Opne the Markets now!!!

User Image Galactic_Stock_Savant Posted - 1 hour ago

$VKTX already 62.25 per share we see 70-80 at open tomorrow shorts are gonna scramble they can’t cover in after hours

User Image Aces_n_Eights Posted - 1 hour ago

$VKTX I hope fifty shares is enough to take me somewhere.

User Image ringo2112 Posted - 1 hour ago

$VKTX not the breakout stock everyone thinks it is.. no buyout , no 1000 pt lol

User Image KnysnaNow Posted - 1 hour ago

@uknic @TrustButVerifi @mhkmjk They (CNBC, et al) are just trying to buy time for their short buddies, while the rest of the investment world pushing the BUY button as fast as they can. Such a game …. Unfortunately, time has run out for them. $VKTX has won.

User Image BioRich Posted - 1 hour ago

@intratio such as? Our model has $FDMT up 3 out of the next 5 trading days and 24.44 by this time next month. Curious what your AI has predicted for $TERN $VKTX $TGTX and $VRNA. Thanks! Like and Follow for more tips/suggestions Let's make some money and Cheers!

User Image HopefulCass Posted - 1 hour ago

$VKTX just 3 weeks ago. Just a reminder to where we were. The $38 gap fill people, myself included, were ultimately very wrong thankfully. But we also were not that far away. $46 this was trading at! Wow.

User Image Smackdabid Posted - 2 hours ago

@Breakoutstockmoves Who's waiting until 2028? I would be extremely surprised if $VKTX is still an independent company by the JPMHCC in January.

User Image samedison Posted - 2 hours ago

$VKTX this is a $1000 stock by 2028 if no Buyout. P3 news today is just Massive. Even @ $200/share this is a steal for big pharma with billions of potential revenue this can generate in 5 years.

User Image ellakim Posted - 2 hours ago

$VKTX pre-market analysis🚀 http://shorturl.re/trending_site

User Image Smackdabid Posted - 2 hours ago

$VKTX No reason to sell the stock now, CEO Lian has basically taken out the majority of risk in owning the stock all the way back up to ATH's and beyond. There's no way in hell this company is not in play after today's CC. $LLY and $NVO execs must be crapping their pants(simulating the effect of their obesity drugs :) We now know Phase 3 is next, speeding up the drug to market by at least 2 years, Oral VK2735 is safe with good tolerability and more effective at higher doses, and results of VK0214 in X-ALD is a near term catalyst. Obesity Week this year will be the best yet for Viking

User Image INEEDMONNEY Posted - 2 hours ago

$ALT damn cnbc loves $VKTX wheres the love?

User Image valuegrowthinvestor1984 Posted - 2 hours ago

$VKTX nope anything under 65 is a gift.

User Image biolover Posted - 2 hours ago

$VKTX this combo will make NASH/ MASh history. Remember tirzapetide has the best anti NASh profile so far ( 73% NAsh resolution after one year or so ), VK 2735 was double effective of tirzapetide in reducing liver fat in obese mice , and vk2735 reduced liver fat in humans up to 59% placebo adjusted in just one month in the phase 1. If you combine it with VK2809 with its fat melting and anti fibrotic characteristics, then NASH will be history. Where is gilead on that? . They wanted to spend 20-30 B a few years ago to get something even mediocre for NASH !

User Image Galactic_Stock_Savant Posted - 2 hours ago

$VKTX 10 billion is delusional that’s nothing the markets 160 b and there’s only 3 drugs on market in weight loss

User Image FatMoneyScience Posted - 2 hours ago

@pharmacisting $vktx is great if you like to start a position with a big market cap for a pretty good drug.

User Image biolover Posted - 2 hours ago

$VKTX next catalyst will be the x ALD data. Will likely be reported before obesity week. Very positive about that as strong basic science support w major role for thyroid hormone on this disease. Good for patients and another great asset derisked from toxicity perspective

User Image TrustButVerifi Posted - 3 hours ago

$VKTX We are trending #1 on ST, but yahoo sleepers have not woken up to reality yet!

User Image TrustButVerifi Posted - 3 hours ago

$VKTX Guy Adami on Fast Money today said 10 Billion for VKTX BO. I think these clowns on CNBC need to do a bit of due diligence before they just throw numbers out. 10 Billion is DELUSIONAL! $20 BILLION MINIMUM!

User Image biolover Posted - 3 hours ago

$VKTX that analyst Annabel who asked about next generation drugs. Was dump question sorry. Viking glp1 gip is expected alone to result in wt loss 25-30 % at year 1 ( based on the slope of wt loss. 15 % at 3 months ) is equivalent to bariatric surgery and if one adds viking new amylin dual agonist it can add 5-10%. It is crazy and the drugs are extremely well tolerated compared to other classes of human medicines. There is no fucking next generation obesity drugs anymore. Let them search other 50 years for the elusive next drugs. 😂

User Image FreddiePowell421 Posted - 3 hours ago

$VKTX pre-market updates🚀 http://per-matket-updates.stocktradings.xyz

User Image TrustButVerifi Posted - 3 hours ago

$VKTX VKTX on Fast Money today They all say BO 100% Go to 34 min mark and listen : https://www.cnbc.com/2018/03/01/fast-money-podcast.html

User Image DG20 Posted - 3 hours ago

$VKTX Newcomers- VKTX has best in class assets. VK2735 + VK2809 is likely the most metabolically active compound ANY company currently possesses incl statins+PSK9 inhibitors. These meds 💊 treat multiple illnesses and benefit humanity in enormous ways from diabetes alone such as LESS blindness, less ESRD, ED, amputations, chronic infections to possibly even chronic fibrotic conditions like scleroderma which has NO treatment (ie. patent for VK2809)… THEY DECREASE CANCER!!! GLP Proven indications… 1) Diabetes 2) Obesity 3) All cause mortality (including sudden cardiac death) 4) Decrease in heart attack / stroke 5) Sleep apnea 6) CHF 7) Chronic Kidney disease 8) Elevated cholesterol/Trigs (VK2809👍) 9) High blood pressure GLP Likely indications… 1) NASH (VK2809👍) 2) Alzheimer’s 3) Female fertility 4) Autoimmunity (including Lupus/Psoriasis) 5) Joint replacements 6) Bariatric surgery 7) Parkinson’s 8) Addiction treatment 9) High risk cancer stratification (ex obesity + HER2 gene)

User Image reecetrade Posted - 3 hours ago

$VKTX too late to hop in?

User Image Lets_Go_Brndn Posted - 3 hours ago

$VKTX This guy deletes his ST account tomorrow after Viking deletes his bank account tomorrow:

Analyst Ratings
Morgan Stanley Overweight Jun 27, 24
HC Wainwright & Co. Buy Jun 24, 24
Truist Securities Buy Jun 17, 24
Raymond James Strong Buy Jun 4, 24
Maxim Group Buy Jun 4, 24
HC Wainwright & Co. Buy Jun 4, 24
Raymond James Strong Buy May 16, 24
Truist Securities Buy May 16, 24
HC Wainwright & Co. Buy Apr 25, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Lian Brian President & CEO President & CEO Jan 31 Sell 24.7 85,000 2,099,500 2,264,882 01/31/24
Lian Brian President & CEO President & CEO Jan 31 Option 1.23 85,000 104,550 2,349,882 01/31/24
Lian Brian President & CEO President & CEO Jan 30 Sell 23.95 35,000 838,250 2,264,882 01/30/24
Lian Brian President & CEO President & CEO Jan 30 Option 1.23 35,000 43,050 2,299,882 01/30/24
Rouan Sarah Kathryn Director Director Jan 19 Sell 23.05 30,000 691,500 01/19/24
Rouan Sarah Kathryn Director Director Jan 19 Option 8.32 30,000 249,600 30,000 01/19/24
ZANTE GREG Chief Financial Offi.. Chief Financial Officer Jan 03 Sell 17.9 15,000 268,500 180,730 01/04/24
Rowland Charles A Jr Director Director May 16 Option 1.08 40,000 43,200 70,000 05/18/23
Rowland Charles A Jr Director Director May 16 Sell 25 40,000 1,000,000 30,000 05/18/23
MACARTNEY LAWSON Director Director May 16 Sell 24 16,000 384,000 47,965 05/18/23
MACARTNEY LAWSON Director Director May 16 Option 1.19 16,000 19,040 63,965 05/18/23
Lian Brian President & CEO President & CEO May 01 Sell 22.45 45,000 1,010,250 2,197,963 05/01/23
MACARTNEY LAWSON Director Director Apr 24 Sell 22 16,000 352,000 47,965 04/24/23
MACARTNEY LAWSON Director Director Apr 24 Option 3.33 16,000 53,280 63,965 04/24/23
Lian Brian President & CEO President & CEO Apr 19 Sell 21.45 35,000 750,750 2,242,963 04/21/23
MACARTNEY LAWSON Director Director Apr 17 Sell 20 20,786 415,720 47,965 04/18/23
MACARTNEY LAWSON Director Director Apr 17 Option 8 20,786 166,288 68,751 04/18/23
Lian Brian President & CEO President & CEO Apr 17 Sell 20.45 155,000 3,169,750 2,277,963 04/18/23
Lian Brian President & CEO President & CEO Apr 17 Option 2.15 125,000 268,750 2,432,963 04/18/23
Mancini Marianna Chief Operating Offi.. Chief Operating Officer Apr 17 Sell 20 12,500 250,000 287,763 04/18/23
Mancini Marianna Chief Operating Offi.. Chief Operating Officer Apr 17 Option 13.07 12,500 163,375 300,263 04/18/23
ZANTE GREG Chief Financial Offi.. Chief Financial Officer Apr 17 Sell 20 7,500 150,000 149,279 04/18/23
ZANTE GREG Chief Financial Offi.. Chief Financial Officer Apr 17 Option 13.07 7,500 98,025 156,779 04/18/23
Lian Brian President & CEO President & CEO Apr 13 Sell 18.45 79,336 1,463,749 2,307,963 04/13/23
Lian Brian President & CEO President & CEO Apr 13 Option 1.88 54,336 102,152 2,387,299 04/13/23
ZANTE GREG Chief Financial Offi.. Chief Financial Officer Apr 11 Sell 18 97,839 1,761,102 149,279 04/13/23
ZANTE GREG Chief Financial Offi.. Chief Financial Officer Apr 11 Option 6.12 97,839 598,775 190,823 04/13/23
Lian Brian President & CEO President & CEO Mar 30 Sell 17.43 243,352 4,241,625 2,232,963 04/03/23
Lian Brian President & CEO President & CEO Mar 30 Option 6.74 203,352 1,370,592 2,322,933 04/03/23
ZANTE GREG Chief Financial Offi.. Chief Financial Officer Mar 30 Sell 17.5 161,940 2,833,950 147,778 04/03/23
ZANTE GREG Chief Financial Offi.. Chief Financial Officer Mar 30 Option 6.55 124,661 816,530 178,689 04/03/23
Mancini Marianna Chief Operating Offi.. Chief Operating Officer Mar 30 Option 9.92 72,200 716,224 261,895 04/03/23
Mancini Marianna Chief Operating Offi.. Chief Operating Officer Mar 28 Sell 15.5 237,805 3,685,978 261,895 03/30/23
Mancini Marianna Chief Operating Offi.. Chief Operating Officer Mar 28 Option 2.98 182,427 543,632 303,137 03/30/23